Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2006 2
2011 5
2012 3
2013 1
2015 2
2017 2
2019 1
2020 4
2021 5
2022 6
2023 6
2024 3
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Immune evasion through mitochondrial transfer in the tumour microenvironment.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, Ishino T, Aki S, Lin J, Kawashima S, Nagasaki J, Ueda Y, Suzuki S, Makinoshima H, Itami M, Nakamura Y, Tatsumi Y, Suenaga Y, Morinaga T, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kiniwa Y, Ichihara E, Hayashi H, Ikeda JI, Hanazawa T, Toyooka S, Mano H, Suzuki T, Osawa T, Kawazu M, Togashi Y. Ikeda H, et al. Nature. 2025 Feb;638(8049):225-236. doi: 10.1038/s41586-024-08439-0. Epub 2025 Jan 22. Nature. 2025. PMID: 39843734 Free PMC article.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: ikeda h. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: ikeda h. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.
Mukohara F, Iwata K, Ishino T, Inozume T, Nagasaki J, Ueda Y, Suzawa K, Ueno T, Ikeda H, Kawase K, Saeki Y, Kawashima S, Yamashita K, Kawahara Y, Nakamura Y, Honobe-Tabuchi A, Watanabe H, Dansako H, Kawamura T, Suzuki Y, Honda H, Mano H, Toyooka S, Kawazu M, Togashi Y. Mukohara F, et al. Among authors: ikeda h. Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2320189121. doi: 10.1073/pnas.2320189121. Epub 2024 Aug 21. Proc Natl Acad Sci U S A. 2024. PMID: 39167601 Free PMC article.
Aging, cancer, and antitumor immunity.
Ikeda H, Togashi Y. Ikeda H, et al. Int J Clin Oncol. 2022 Feb;27(2):316-322. doi: 10.1007/s10147-021-01913-z. Epub 2021 Mar 30. Int J Clin Oncol. 2022. PMID: 33783658 Review.
Publisher Correction: Immune evasion through mitochondrial transfer in the tumour microenvironment.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, Ishino T, Aki S, Lin J, Kawashima S, Nagasaki J, Ueda Y, Suzuki S, Makinoshima H, Itami M, Nakamura Y, Tatsumi Y, Suenaga Y, Morinaga T, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kiniwa Y, Ichihara E, Hayashi H, Ikeda JI, Hanazawa T, Toyooka S, Mano H, Suzuki T, Osawa T, Kawazu M, Togashi Y. Ikeda H, et al. Nature. 2025 Mar;639(8053):E5. doi: 10.1038/s41586-025-08764-y. Nature. 2025. PMID: 39948434 Free PMC article. No abstract available.
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: ikeda h. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2019-2020: General view of the pathogens' antibacterial susceptibility.
Tokimatsu I, Matsumoto T, Tsukada H, Fujikura Y, Miki M, Morinaga Y, Sato J, Wakamura T, Kiyota H, Tateda K, Yanagisawa H, Sasaki T, Ikeda H, Horikawa H, Takahashi H, Seki M, Mori Y, Takeda H, Kurai D, Hasegawa N, Uwamino Y, Kudo M, Yamamoto M, Nagano Y, Nomura S, Tetsuka T, Hosokai M, Aoki N, Yamamoto Y, Iinuma Y, Mikamo H, Suematsu H, Maruyama T, Kawabata A, Sugaki Y, Nakamura A, Fujikawa Y, Fukumori T, Ukimura A, Kakeya H, Niki M, Yoshida K, Kobashi Y, Tokuyasu H, Yatera K, Ikegami H, Fujita M, Matsumoto T, Yanagihara K, Matsuda J, Hiramatsu K, Shinzato T. Tokimatsu I, et al. Among authors: ikeda h. J Infect Chemother. 2023 Aug;29(8):731-743. doi: 10.1016/j.jiac.2023.04.008. Epub 2023 Apr 26. J Infect Chemother. 2023. PMID: 37116613
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
Okada A, Sakata Y, Oya Y, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakagami T. Okada A, et al. Among authors: ikeda h. Lung Cancer. 2025 Jun;204:108589. doi: 10.1016/j.lungcan.2025.108589. Epub 2025 May 22. Lung Cancer. 2025. PMID: 40413921
Histologic transformation of epidermal growth factor receptor-mutated lung cancer.
Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Fujimoto D, et al. Among authors: ikeda h. Eur J Cancer. 2022 May;166:41-50. doi: 10.1016/j.ejca.2022.02.006. Epub 2022 Mar 9. Eur J Cancer. 2022. PMID: 35278824
43 results